Literature DB >> 3893600

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome.

D A Curson, T R Barnes, R W Bamber, S D Platt, S R Hirsch, J C Duffy.   

Abstract

The relapse and admission histories revealed a positive correlation between number of schizophrenic episodes and time on maintenance medication, probably reflecting severity of illness. Relapse rates after drug discontinuation rose to 45% within 13 months. There were no differences of predictive value between those relapsing on or off medication. The relationship between relapse rates, drug treatment, and social outcome is complex; antipsychotic drugs may postpone relapse, and frequent relapses might inhibit improvement in social performance long after florid symptoms have been controlled by medication.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893600     DOI: 10.1192/bjp.146.5.474

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

1.  Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.

Authors:  Michael J Honsberger; Jane R Taylor; Philip R Corlett
Journal:  Schizophr Res       Date:  2015-02-24       Impact factor: 4.939

2.  Does short term placebo treatment of chronic schizophrenia produce long term harm?

Authors:  D A Curson; S R Hirsch; S D Platt; R W Bamber; T R Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-20

3.  Psychiatric morbidity of a long stay hospital population with chronic schizophrenia and implications for future community care.

Authors:  D A Curson; M Patel; P F Liddle; T R Barnes
Journal:  BMJ       Date:  1988-10-01

4.  Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

Authors:  R J Hardie; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

5.  Identifying Modifiable Risk Factors for Relapse in Patients With Schizophrenia in China.

Authors:  Wei-Feng Mi; Xiao-Min Chen; Teng-Teng Fan; Serik Tabarak; Jing-Bo Xiao; Yong-Zhi Cao; Xiao-Yu Li; Yan-Ping Bao; Ying Han; Ling-Zhi Li; Ying Shi; Li-Hua Guo; Xiao-Zhi Wang; Yong-Qiao Liu; Zhan-Min Wang; Jing-Xu Chen; Feng-Chun Wu; Wen-Bin Ma; Hua-Fang Li; Wei-Dong Xiao; Fei-Hu Liu; Wen Xie; Hong-Yan Zhang; Lin Lu
Journal:  Front Psychiatry       Date:  2020-09-11       Impact factor: 4.157

6.  The effects of cognitive therapy on hallucinations in patients with schizophrenia.

Authors:  Alanna Propst
Journal:  Mcgill J Med       Date:  2011-06

7.  Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate.

Authors:  Katy Mason; Joshua Barnett; Sofia Pappa
Journal:  Ther Adv Psychopharmacol       Date:  2021-07-20

Review 8.  The nature of relapse in schizophrenia.

Authors:  Robin Emsley; Bonginkosi Chiliza; Laila Asmal; Brian H Harvey
Journal:  BMC Psychiatry       Date:  2013-02-08       Impact factor: 3.630

9.  Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia.

Authors:  Gi Hyeon Seo; Boung Chul Lee; Hye Ok Kim
Journal:  Ann Gen Psychiatry       Date:  2020-01-14       Impact factor: 3.455

Review 10.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.